Over the past ten years, cancer immunotherapy particularly with immune checkpoint inhibitors (ICI) targeting the Programmed Death-1 (PD-1)/ligand-1 (PD-L1) axis, has revolutionized the outcome of several aggressive cancers, such as metastatic melanoma, non-small-cell lung cancer (NSCLC) or renal cell carcinoma [8]. Here, CD274 is linked to cancer.